MOTIVATION LETTER The DayOne Accelerator supports early-stage ventures that improve pharmaceutical research and development. My venture, currently pre-incorporation, directly addresses a critical bottleneck in addiction pharmacotherapy: the inability to predict a compound's addiction liability before clinical trials. I have built and validated three computational platforms that solve this problem. IMPRINT screens small molecules for addiction-liability potential using a Bayesian framework derived from my Conjunctive Consolidation Threshold model. TOPOLOGIX applies topological data analysis with persistent homology and bipartite simplicial complexes to map drug-protein interactions, with a validated MVP for hERG cardiotoxicity screening. GATE evaluates neural-stimulation safety for brain-computer interfaces. These platforms are validated. The CCT model, validated through ODE/RK45 and Bayesian MCMC simulations, demonstrates an 85.8 percent reduction in encoding probability for reward-memory formation, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed. A provisional patent on the CCT core architecture is filed for Q3 2026. I am a 29-year-old Nigerian independent researcher with a B.Pharm from the University of Ibadan and a PCN pharmacist license. My work has received endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. Gershman provided my arXiv endorsement. My three sole-authored preprints are published on OSF and Zenodo with DOIs. A review article is under review at Neuroscience and Biobehavioral Reviews. A co-authored paper is under review at Alcohol. I built these platforms and wrote every line of code myself using Python, R, TDA libraries, and molecular docking tools. I currently work as National Product Manager at Synthcare in Lagos. DayOne's focus on discovery tools and enabling technologies matches my venture exactly. My platforms are a reusable, scalable infrastructure for pharmaceutical R&D in addiction and drug safety, not a single drug candidate. The equity-free, fee-free structure of DayOne is critical for a founder based in Nigeria with no institutional lab or university affiliation. I am applying for the researcher track and am eligible for early-career, pre-PhD, and LMIC-focused programmes. I will begin an MSc in computational neuroscience at MUG/Graz in October 2026. DayOne would accelerate my path from independent researcher to founder before that enrolment. SHORT ESSAY: VENTURE DESCRIPTION My venture is a pre-incorporation TechBio startup that provides AI-driven platforms for addiction-liability screening and drug-protein interaction analysis. The core technology is the Conjunctive Consolidation Threshold model, a tripartite pharmacological framework that predicts how a compound affects reward-memory encoding. The model was validated through computational simulation: encoding probability dropped from 0.855 to 0.122, an 85.8 percent reduction. The platforms built on this model are IMPRINT, TOPOLOGIX, and GATE. IMPRINT screens compounds for addiction liability. TOPOLOGIX uses topological data analysis with persistent homology to map drug-protein interactions and predict off-target effects like hERG cardiotoxicity. GATE evaluates safety of neural stimulation protocols for BCI applications. The venture targets pharmaceutical companies, contract research organizations, and regulatory agencies that need preclinical screening tools to reduce late-stage attrition. The value proposition is clear: a computational screen that costs less than one percent of an animal study and returns results in hours, not months. The provisional patent protects the CCT core architecture. The endorsements from Berridge, Gershman, Daw, and Mattar provide scientific credibility. The venture has raised zero dilutive funding and is at pre-seed stage, meeting DayOne's eligibility criteria. SHORT ESSAY: TEAM AND EXPERTISE I am the sole founder and lead researcher. My background combines pharmacy, computational neuroscience, and software engineering. I hold a B.Pharm from the University of Ibadan with a CGPA of 5.1 out of 7.0, equivalent to a German 1.9. I am a licensed pharmacist with the Pharmacists Council of Nigeria. I have worked as a clinical pharmacist at Ramset Pharmacy and as a research assistant at the Centre for Drug Discovery, Development and Production, where I performed NMDA and insulin docking studies. I built the bioinformatics surveillance pipeline for AMR genomics at the Ghanaian-South African Research Unit. My technical skills include Python with scipy, numpy, PyMC, and ODE solvers; R; topological data analysis with Ripser and Gudhi; molecular docking with AutoDock and GROMACS; and neural simulation with NEURON and Brian2. I built the three platforms alone, including the full-stack development with Supabase, Postgres, and JavaScript. The endorsements from four leading computational neuroscientists validate the scientific foundation. I am currently National Product Manager at Synthcare, managing pharmaceutical product strategy across Nigeria. This commercial experience directly supports the go-to-market planning for my venture. CHECKLIST - [ ] Complete DayOne Accelerator online application form at cbinsights.com/investor/dayone-accelerator - [ ] Upload motivation letter as PDF - [ ] Upload short essay on venture description as PDF - [ ] Upload short essay on team and expertise as PDF - [ ] Prepare one-page executive summary of the venture with platform descriptions and validation results - [ ] Prepare slide deck (maximum 10 slides) covering problem, solution, validation, team, market, and ask - [ ] Gather letters of endorsement from Kent Berridge, Samuel Gershman, Nathaniel Daw, and Marcelo Mattar - [ ] Prepare provisional patent filing summary document - [ ] Compile links to all three preprints on OSF and Zenodo with DOIs - [ ] Prepare GitHub repository links for IMPRINT, TOPOLOGIX, and GATE - [ ] Verify eligibility for pre-incorporation ventures based in Nigeria (DayOne geography is EU/France-focused; confirm remote participation policy) - [ ] Confirm that no dilutive funding has been raised (less than 10M USD threshold) EDITOR NOTES - Eligibility risk: DayOne Accelerator is based in France and focuses on EU-based ventures. Eniola is in Lagos, Nigeria. The application must explicitly address remote participation and any visa or relocation requirements. Confirm with programme staff before submitting. - Verification needed: The provisional patent filing date of Q3 2026 is a future date. Confirm whether the patent has been filed or if this is a planned filing. If not yet filed, adjust language to "provisional patent application in preparation." - Gap: The profile does not specify a company name for the venture. The application materials refer to "the venture" but a formal name may be required. Eniola should decide on a working name before submitting. - Gap: No financial projections or business model details are in the profile. The short essays focus on science and technology. DayOne may expect a basic revenue model or market size estimate. Eniola should prepare a brief financial section for the slide deck. - Gap: The profile lists "drug resistance prediction" in the strategy notes, but the platforms described focus on addiction liability and drug safety, not antimicrobial resistance. Clarify whether the venture also addresses AMR or if this was a misalignment in the research. If AMR is part of the plan, include the GHRU-GSAR bioinformatics work as evidence.